{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:19:57Z","timestamp":1780579197303,"version":"3.54.1"},"reference-count":22,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,8,2]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Cytogenetic and molecular aberrations are the strongest factors in determining outcome in acute myeloid leukaemia (AML). AML with complex karyotype confers a particularly poor prognosis and is associated with morphologic dysplasia. Flow cytometric immunophenotyping (FCI) has been investigated in defining dysplasia within myelodysplastic syndromes, but little is known about immunophenotypic dysplasia in AML and correlation with genetic abnormalities. This study aimed to explore differences in antigen expression by FCI in AML with complex karyotype (AML-CK) and AML with complex karyotype and <jats:italic>TP53<\/jats:italic> mutations (AML-TP53) compared with AML with normal karyotype (AML-NK).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-five cases of AML-CK, 13 of which had abnormalities of <jats:italic>TP53<\/jats:italic>, were compared with 83 cases of AML-NK using FCI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our findings demonstrated brighter expression of CD34 with decreased CD33 and aberrant expression of CD5 in blasts of AML-CK, while AML-TP53 blasts exhibited brighter expression of CD13. Granulocytes in AML-CK exhibited brighter expression of CD5, CD7, CD10 and CD14, with brighter CD3 also seen in AML-TP53.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that immunophenotypic dysplasia correlates with complex karyotype and <jats:italic>TP53<\/jats:italic> mutation, including increased expression of T-cell antigens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2018-205348","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T12:24:07Z","timestamp":1535718247000},"page":"1051-1059","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and <i>TP53<\/i> mutations"],"prefix":"10.1136","volume":"71","author":[{"given":"Katelyn C","family":"Dannheim","sequence":"first","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Dal Cin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga K","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"2025092505113870000_71.12.1051.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00040-7"},{"key":"2025092505113870000_71.12.1051.2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2001.0152"},{"key":"2025092505113870000_71.12.1051.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"2025092505113870000_71.12.1051.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254441"},{"key":"2025092505113870000_71.12.1051.5","unstructured":"International Agency for Research on Cancer. In: Swerdlow SH , Campo E , Harris NL , WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edn. France: Lyon, 2017."},{"key":"2025092505113870000_71.12.1051.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02511.x"},{"key":"2025092505113870000_71.12.1051.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.04.007"},{"key":"2025092505113870000_71.12.1051.8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.143"},{"key":"2025092505113870000_71.12.1051.9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.173"},{"key":"2025092505113870000_71.12.1051.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3589"},{"key":"2025092505113870000_71.12.1051.11","unstructured":"Swerdlow SH , Campo E . International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. 4. edn. France: Lyon, 2008."},{"key":"2025092505113870000_71.12.1051.12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.55"},{"key":"2025092505113870000_71.12.1051.13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.161"},{"key":"2025092505113870000_71.12.1051.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.979"},{"key":"2025092505113870000_71.12.1051.15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005801"},{"key":"2025092505113870000_71.12.1051.16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.30"},{"key":"2025092505113870000_71.12.1051.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2768"},{"key":"2025092505113870000_71.12.1051.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-153700"},{"key":"2025092505113870000_71.12.1051.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098764"},{"key":"2025092505113870000_71.12.1051.20","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203863"},{"key":"2025092505113870000_71.12.1051.21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"key":"2025092505113870000_71.12.1051.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2018-205348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:11:47Z","timestamp":1758802307000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2018-205348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,11,30]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/jclinpath-2018-205348"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2018-205348","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]}}}